Overcoming EGFR Resistance in Metastatic Colorectal Cancer Using Vitamin C: A Review

Targeted monoclonal antibody therapy against Epidermal Growth Factor Receptor (EGFR) is a leading treatment modality against metastatic colorectal cancer (mCRC). However, with the emergence of KRAS and BRAF mutations, resistance was inevitable. Cells harboring these mutations overexpress Glucose Tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Machmouchi, Ahmad, Chehade, Laudy, Temraz, Sally, Shamseddine, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045351/
https://www.ncbi.nlm.nih.gov/pubmed/36979659
http://dx.doi.org/10.3390/biomedicines11030678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045351/
https://www.ncbi.nlm.nih.gov/pubmed/36979659
http://dx.doi.org/10.3390/biomedicines11030678

Ejemplares similares